Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: RADEK MICA/AFP via Getty Images

Moderna on Tuesday announced that its coronavirus vaccine was found to be safe and 100% effective at protecting against COVID-19 in a Phase 3 trial of more than 3,700 participants between the ages of 12 and 17.

Why it matters: Moderna CEO Stéphane Bancel said the company plans to submit its data to global regulators in early June, paving the way for an emergency use authorization for adolescents.

  • If approved by the U.S. Food and Drug Administration, it would increase the number of available vaccines for teenagers before the school year starts, per CNBC.
  • Moderna's vaccine is the second to show high efficacy in younger age groups, following Pfizer, which received an FDA emergency use authorization for adolescents earlier this month.

Details: Moderna's clinical trial included 3,732 adolescent participants ages 12 to 17, with one group receiving the vaccine and another receiving a placebo.

  • No virus cases were observed in the vaccine group after two doses, "resulting in a vaccine efficacy of 100% starting 14 days after the second dose," according to the company.
  • The vaccine was found to be 93% effective after one dose.

What to watch: The study is ongoing, and participants will continue to be monitored for 12 months after their second injection. Moderna says the results are subject to change based on ongoing data collection.

  • The company plans to submit their results to a peer-reviewed publication.

Go deeper

Axios-Ipsos poll: Re-emerging without trust

Data: Axios/Ipsos Poll; Note: 3.2% margin of error; Chart: Axios Visuals

Americans are taking off their masks and re-engaging publicly at levels not seen since the start of the pandemic, with the most dramatic shifts in people over 50 and those who've been vaccinated, according to the latest installment of the Axios/Ipsos Coronavirus Index.

The big picture: It's happening despite significant distrust over strangers' honesty about their COVID-19 vaccination status and amid major confusion over Centers for Disease Control and Prevention guidance on mask use and social distancing for those vaccinated.

May 24, 2021 - Health

State Department warns against travel to Japan

Security guards keep watch next to the Olympic Rings while people take part in a protest against the hosting of the 2020 Tokyo Olympic Games. Photo by KAZUHIRO NOGI/AFP via Getty Images

The State Department issued a "Do Not Travel" warning for Japan, citing the surge in coronavirus cases.

Why it matters: The Tokyo Olympics are scheduled to run from July 23 to August 8, with thousands of athletes from all over the globe set to arrive in the city.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!